肠镜检查发现低风险腺瘤后该怎么办?
创作:szx 审核:szx 02月22日
  • 纳入12项研究进行荟萃分析,对比不同结肠镜检查结果对应的结直肠癌(CRC)发病风险及死亡风险;
  • 共涉及510,019名接受结肠镜检查的患者,平均随访8.5年;
  • 检测到低风险腺瘤的患者,其CRC发病率比无腺瘤者略有增加(OR 1.26),但CRC相关死亡率无显著变化;
  • 检测到高风险腺瘤的患者的CRC发病率及相关死亡率,均显著高于低风险腺瘤者(OR分别为2.35和2.48)和无腺瘤者(OR分别为2.92和2.69)。
主编推荐语
szx
来自Gastroenterology上发表的一项荟萃分析结果,对12项研究(共涉及超过50万人)的数据进行总结后发现,在结肠镜检查中发现低风险腺瘤的患者,其结直肠癌发病率仅略高于未检测到腺瘤的患者,而结直肠癌相关死亡率无明显变化。另外,对于检测到高风险腺瘤的患者,其结直肠癌发病率及相关死亡率均明显升高。该研究结果提示,检测到低风险腺瘤后的随访措施应与未检测到腺瘤者相同。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:17.373]

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review And Meta-Analysis

相比于未检测到腺瘤者,结肠镜检查后发现低风险或高风险腺瘤者的结直肠癌风险及相关死亡率:系统性综述与荟萃分析

10.1053/j.gastro.2021.01.214

01-28, Article

Abstract & Authors:展开

Abstract:收起
Background & Aims: The risk of metachronous colorectal cancer (CRC) among patients with no adenomas, low-risk adenomas (LRAs), or high-risk adenomas (HRAs), detected at index colonoscopy, is unclear. We performed a systematic review and meta-analysis to compare incidence rates of metachronous CRC and CRC-related mortality after a baseline colonoscopy for each group.
Methods: We searched the Pubmed, EMBASE, Google Scholar, and Cochrane databases for studies that reported the incidence of CRC and adenoma characteristics after colonoscopy. The primary outcome was odds of metachronous CRC and CRC-related mortality per 10,000 person-years of follow-up after baseline colonoscopy for all the groups.
Results: Our final analysis included 12 studies with 510,019 patients (mean age, 59.2 ± 2.6 years; 55% male; mean duration of follow up, 8.5 ± 3.3 years). The incidence of CRC per 10,000 person-years was marginally higher for patients with LRAs compared to those with no adenomas (4.5 vs 3.4; odds ratio [OR], 1.26; 95% CI, 1.06–1.51; I2=0), but significantly higher for patients with HRAs compared to those with no adenoma ( 13.8 vs 3.4; odds ratio [OR], 2.92; 95% CI, 2.31–3.69; I2=0 ) and patients with HRAs compared to LRAs (13.81 vs 4.5; OR, 2.35; 95% CI, 1.72–3.20; I2=55%). However, the CRC-related mortality per 10,000 person-years did not differ significantly for patients with LRAs compared to no adenomas (OR, 1.15; 95% CI, 0.76–1.74; I2=0) but was significantly higher in persons with HRAs compared with LRAs (OR, 2.48; 95% CI, 1.30–4.75; I2=38%) and no adenomas (OR, 2.69; 95% CI, 1.87–3.87; I2=0).
Conclusions: The results of this systematic review and meta-analysis demonstrate that the risk of metachronous CRC and mortality is significantly higher for patients with HRAs, but this risk is very low in patients with LRAs, comparable to patients with no adenomas. Follow-up of patients with LRAs detected at index colonoscopy should be the same as for persons with no adenomas.

First Authors:
Abhiram Duvvuri

Correspondence Authors:
Abhiram Duvvuri

All Authors:
Abhiram Duvvuri,Viveksandeep Thoguluva Chandrasekar,Sachin Srinivasan,Anvesh Narimiti,ChandraShekhar Dasari,Venkat Nutalapati,Kevin F Kennedy,Marco Spadaccini,Giulio Antonelli,Madhav Desai,Prashanth Vennalaganti,Divyanshoo Kohli,Michal F Kaminski,Alessandro Repici,Cesare Hassan,Prateek Sharma

评论